The broad goals of the ADRC at Columbia University include creating an infrastructure for research on AD and related disorders, fostering interdisciplinary collaborations across many departments, providing a rich training environment, and supporting outreach and patient recruitment. More globally, the goals of our ADRC extend to include participation in all national coordinating efforts, working with the national network of AD centers, and working with the National Institute on Aging and other organizations in their advocacy efforts. Embedded within these broad goals, in this reapplication a concentration will be placed on better defining normal aging and the transition from normal aging to the earliest stages of AD. The Administrative Core will act as the executive governing body of the ADRC that, with the guidance of its various committees, will provide the vision and leadership necessary to achieve the ADRC s goals. The Administrative Core will implement this vision by exercising managerial oversight over all aspects of the ADRC, which includes assuring the highest standards of scientific and bioethical conduct and assuring a judicious use of resources and funds. Dr. Scott Small will lead the core together with Dr. Richard Mayeux (co-director of the ADRC), Drs. Lawrence Honig and Yaakov Stern (deputy directors of the ADRC), Ms. Rosann Costa (Administrator of the ADRC), and Mr. Kevin Ramratan (Financial coordinator of the ADRC). Together and through continuous meetings they will achieve the ADRC s goals via a number of specific aims. These include: 1) Organize and direct monthly meetings with an executive committee made up of all core and project leaders. 2) Work closely with an external and internal advisory committee revamped to better fit the updated goals of the ADRC. 3) Work closely with the other cores to assure timely delivery of high quality clinical, genetic, and neuroimaging data, as well as biospecimens, to national consortia. 4) Work closely with a newly assembled resource committee . 5) Work closely with a newly assembled pilot project committee . 6) Assure and enhance the ADRC s outreach, advocacy, education, and training mission.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG008702-27
Application #
9088232
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2016-06-01
Budget End
2017-05-31
Support Year
27
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Winawer, Melodie R; Griffin, Nicole G; Samanamud, Jorge et al. (2018) Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy. Ann Neurol 83:1133-1146
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416
Qureshi, Yasir H; Patel, Vivek M; Berman, Diego E et al. (2018) An Alzheimer's Disease-Linked Loss-of-Function CLN5 Variant Impairs Cathepsin D Maturation, Consistent with a Retromer Trafficking Defect. Mol Cell Biol 38:
Reitz, Christiane (2018) Retromer Dysfunction and Neurodegenerative Disease. Curr Genomics 19:279-288
Tariciotti, Leonardo; Casadei, Matthew; Honig, Lawrence S et al. (2018) Clinical Experience with Cerebrospinal Fluid A?42, Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia. J Alzheimers Dis 65:1417-1425
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Masucci, Michael D; Lister, Amanda; Corcoran, Cheryl M et al. (2018) Motor Dysfunction as a Risk Factor for Conversion to Psychosis Independent of Medication Use in a Psychosis-Risk Cohort. J Nerv Ment Dis 206:356-361

Showing the most recent 10 out of 640 publications